Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo.

Autor: Greenblatt DJ; Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, New England Medical Center Hospital, Boston 02111, USA. Dgreenblatt@infonet.tufts.edu, Harmatz JS, von Moltke LL, Ehrenberg BL, Harrel L, Corbett K, Counihan M, Graf JA, Darwish M, Mertzanis P, Martin PT, Cevallos WH, Shader RI

Publikováno v: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 1998 Nov; Vol. 64 (5), pp. 553-61.

Absolute bioavailability of bromfenac in humans.

Autor: Gumbhir-Shah K; Wyeth-Ayerst Research, Philadelphia, PA 19101, USA., Cevallos WH, DeCleene SA, Halstenson CE, Korth-Bradley JM

Publikováno v: The Annals of pharmacotherapy [Ann Pharmacother] 1997 Apr; Vol. 31 (4), pp. 395-9.

Bromfenac disposition in patients with impaired kidney function.

Autor: Ermer JC; Department of Pharmacokinetics, Wyeth-Ayerst Research, Philadelphia, Pa., USA., Boni JP, Cevallos WH, DeCleene S, Burghart P, Rudnick MR, Fruncillo RJ, Berns JS, Cohen RM

Publikováno v: Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 1997 Mar; Vol. 61 (3), pp. 312-8.

Lack of interaction between bromfenac and methotrexate in patients with rheumatoid arthritis.

Autor: Gumbhir-Shah K; Department of Clinical Pharmacokinetics, Wyeth-Ayerst Research, Philadelphia, PA 19101-8299, USA., Cevallos WH, DeCleene SA, Korth-Bradley JM

Publikováno v: The Journal of rheumatology [J Rheumatol] 1996 Jun; Vol. 23 (6), pp. 984-9.